Given EW’s historical P/E premium versus peers, the current forecast implies modest multiple expansion as product pipeline milestones are achieved. Analysts suggest adding positions on dips to $91–$92. In total, we are pretty happy with Edwards Lifesciences' performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a respectable growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. In the United States, the company’s leading SAPIEN 3 Ultra RESILIA platform continues to demonstrate strong performance. Sales growth in Europe was also supported by the continued expansion of the platform. In Japan, Edwards remains dedicated to addressing the significant undertreatment of aortic stenosis among the substantial elderly population. Advanced technical indicators show a bullish MACD crossover in EW, aligning with consensus forecasts suggesting a 7% appreciation by the next quarter-end.
